The primary aim of this project is to identify next generation small molecules targeting epigenetic proteins able to increase SMN protein and evaluate their therapeutic potential in SMA animal models alone and as an add‐on treatment. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.